Complement Factor H antibodies from lung cancer patients induce complement-dependent lysis of tumor cells, suggesting a novel immunotherapeutic strategy

Cancer Immunology Research

Volumn 3, Issue 12, 2015, Pages 1325-1332

  Campa, Michael J ^a   Gottlin, Elizabeth B ^a   Bushey, Ryan T ^a   Patz, Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H; EPITOPE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G;

A549 CELL LINE; ARTICLE; BINDING SITE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CELL KILLING; CELL PROTECTION; CELL SURFACE; COLUMN CHROMATOGRAPHY; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NON SMALL CELL LUNG CANCER; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

AUTOANTIBODIES; CELL LINE, TUMOR; COMPLEMENT C3B; COMPLEMENT FACTOR H; EPITOPES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 84962081912     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0122     Document Type: Article

References (28)

1. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009; 58: 1535-44.
2. Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010; 16: 3226-31.
3. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 355-67.
4. Ferreira VP, Pangburn MK, Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010; 47: 2187-97.
5. Kajander T, Lehtinen MJ, Hyvarinen S, Bhattacharjee A, Leung E, Isenman DE, et al. Dual interaction offactor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A 2011; 108: 2897-902.
6. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 2011; 18: 463-70.
7. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 2007; 178: 5991-8.
8. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000; 164: 6075-81.
9. Wilczek E, Rzepko R, Nowis D, Legat M, Golab J, Glab M, et al. The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 2008; 122: 2030-7.
10. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998; 113: 173-82.
11. Slootstra JW, Puijk WC, Ligtvoet GJ, Langeveld JP, Meloen RH. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol Divers 1996; 1: 87-96.
12. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol 2008; 181: 2610-9.
13. Schmidt CQ, Herbert AP, Hocking HG, Uhrin D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol 2008; 151: 14-24.
14. Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 2006; 177: 6308-16.
15. Jozsi M, Heinen S, Hartmann A, Ostrowicz CW, Halbich S, Richter H, et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 2006; 17: 170-7.
16. Ferreira VP, Herbert AP, Cortes C, McKee KA, Blaum BS, Esswein ST, et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009; 182: 7009-18.
17. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5: 520.
18. Perkins SJ, Nan R, Li K, Khan S, Miller A. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology 2012; 217: 281-97.
19. Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB. Anti-factorHautoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost 2010; 36: 633-40.
20. Blanc C, Roumenina LT, Ashraf Y, Hyvarinen S, Sethi SK, Ranchin B, et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012; 189: 3528-37.
21. Thiele M, Bernhagen J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid Redox Signal 2005; 7: 1234-48.
22. Ceccarelli J, Delfino L, Zappia E, Castellani P, Borghi M, Ferrini S, et al. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer 2008; 123: 1770-8.
23. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991; 21: 11-6.
24. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2: 599.
25. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40(2-4): 109-23.
26. Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 2001; 28: 12-20.
27. Jager D, Knuth A. Antibodies and vaccines - hope or illusion? Breast 2005; 14: 631-5.
28. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods 2009; 158: 171-9.